Larvol Delta - Mateon-is-Selected-by-IBM-Watson-Health-for-the-Use-of-IBM-Clinical-Development-Solution-at-No-Cost-for-Phase-II-Clinical-Trial-of-OT101-for-COVID19

trabedersen (OT-101) - Autotelic, Mateon Therapeutics

https://www.globenewswire.com/news-release/2020/06/24/2052621/0/en/Mateon-is-Selected-by-IBM-Watson-Health-for-the-Use-of-IBM-Clinical-Development-Solution-at-No-Cost-for-Phase-II-Clinical-Trial-of-OT-101-for-COVID-19.html

Jun 24, 2020

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next